NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

Completed

Conditions: NAFLD
Chronic or Recovered Hepatitis D
NASH
Chronic or Recovered Hepatitis B
Chronic or Recovered Hepatitis C

First Posted Date: 2023-01-03

Last Posted Date: 2025-05-16

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 233

Registration Number: NCT05669677

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Phase 2

Recruiting

Conditions: Metastatic Salivary Gland Carcinoma
Unresectable Salivary Gland Carcinoma
Locally Advanced Salivary Gland Carcinoma
Recurrent Salivary Gland Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Darolutamide
Drug: Leuprolide Acetate
Procedure: Magnetic Resonance Imaging

First Posted Date: 2023-01-03

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT05669664

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 23 locations

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Phase 1

Recruiting

Conditions: Papillary Renal Cell Carcinoma (Prcc)
Advanced Clear Cell Renal Carcinoma (Ccrcc)

Interventions: Drug: Sasanlimab
Drug: Palbocicilib

First Posted Date: 2022-12-27

Last Posted Date: 2025-03-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT05665361

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase 1

Suspended

Conditions: Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Carcinomas
Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant
Biological: H1299 Cell Lysates
Drug: N-803
Device: Ventana PD-L1 (SP263 or SP142) assay

First Posted Date: 2022-12-08

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05642195

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Phase 2

Recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Panitumumab
Drug: Sotorasib

First Posted Date: 2022-12-06

Last Posted Date: 2025-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 105

Registration Number: NCT05638295

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States

and more 156 locations

Testing ONC201 to Prevent Colorectal Cancer

Phase 1

Not yet recruiting

Conditions: Colorectal Adenomatous Polyp
Colorectal Carcinoma
Multiple Adenomatous Polyps
Familial Adenomatous Polyposis

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Colonoscopy
Drug: Dordaviprone
Other: Questionnaire Administration
Procedure: Sigmoidoscopy

First Posted Date: 2022-11-30

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT05630794

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 2 locations

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1

Recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Recurrent Follicular Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Refractory Follicular Lymphoma

Interventions: Drug: Belinostat
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Pharmacokinetic Study
Procedure: Positron Emission Tomography and Computed Tomography Scan
Drug: Tazemetostat

First Posted Date: 2022-11-25

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT05627245

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States

and more 7 locations

Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)

Recruiting

Conditions: Chronic Hepatitis B Virus (Hbv)

First Posted Date: 2022-11-18

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 255

Registration Number: NCT05621304

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Not Applicable

Recruiting

Conditions: Acute Lymphoblastic Leukemia
B-All

Interventions: Diagnostic Test: NGS testing

First Posted Date: 2022-11-18

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT05621291

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 5 locations

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Phase 2

Recruiting

Conditions: Prostate Adenocarcinoma
Prostatic Neoplasms
Prostate Cancer

Interventions: Drug: 18F-DCFPyL
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2022-11-15

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT05616650

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy